MELODY-1: A PILOT STUDY OF MACITENTAN IN PULMONARY HYPERTENSION DUE TO LEFT VENTRICULAR DYSFUNCTION

The main study endpoint, related to safety, assessed a composite of significant fluid retention (weight gain >=5 kg/>=5 % due to fluid overload or the need for parenteral administration of diuretics) or worsening in New York Heart Association functional class from baseline to end of treatment.

Saved in:
Bibliographic Details
Published inJournal of the American College of Cardiology Vol. 69; no. 11; p. 1880
Main Authors Vachiery, Jean-Luc, Delcroix, Marion, Al-Hiti, Hikmet, Efficace, Michela, Hutyra, Martin, Lack, Gabriela, Papadakis, Kelly, Rubin, Lewis
Format Journal Article
LanguageEnglish
Published New York Elsevier Inc 21.03.2017
Elsevier Limited
Subjects
Cardiology
Cardiovascular
Internal Medicine
Pulmonary hypertension
Retention
Online AccessGet full text

Cover

More Information
Summary:The main study endpoint, related to safety, assessed a composite of significant fluid retention (weight gain >=5 kg/>=5 % due to fluid overload or the need for parenteral administration of diuretics) or worsening in New York Heart Association functional class from baseline to end of treatment.
ISSN:0735-1097
1558-3597
DOI:10.1016/S0735-1097(17)35269-5